Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Laying pipe

Genomics company CuraGen Corp. and anti-infective company Cubist Pharmaceuticals Inc., both of which have thin clinical pipelines, had very different motivations for recent clinical in-licensing deals. CRGN says knowledge from its systems biology research led it to seek out compounds targeting histone deacetylase (HDAC) inhibitors. By contrast, CBST wanted to leverage its clinical and regulatory development expertise, which were honed developing Cubicin daptomycin.

Under its deal with TopoTarget A/S, CRGN (New Haven, Conn.) received exclusive ex-European development and commercialization rights to PXD101, an HDAC inhibitor in Phase I testing to treat advanced solid tumors.

CRGN also received an option to license additional HDAC compounds. It will make a $5 million equity investment in TopoTarget (Copenhagen, Denmark), will pay another $5 million

Read the full 1201 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers